Janus Henderson Global Life Sciences Fund Class N Shares
JFNNX
NASDAQ- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management - Global
- Address
- Denver CO 80206 Denver CO United States of America 80206
- IPO Date
- Jan 26, 2018
- CIK
- 0000277751
- Website
- janushenderson.com
- Similar Companies
- Business
- Janus Henderson Global Life Sciences Fund Class N Shares (JFNNX) is an open-end equity mutual fund managed by Janus Henderson Investors that seeks long-term growth of capital by investing at least 80% of its net assets in securities of companies with a life sciences orientation, including at least 25% in the life sciences sector; it maintains a balanced portfolio across biotechnology, health care services, medical devices, and pharmaceuticals, with diversification across market capitalizations and geographies, primarily U.S. stocks (approximately 82%), non-U.S. stocks (16%), and minimal cash or other assets. The fund targets companies addressing unmet medical needs or improving health care system efficiency, employing fundamental analysis with a bottom-up stock-picking approach benchmarked against the MSCI World Health Care Index. Key holdings include Eli Lilly and Co., AstraZeneca PLC, Johnson & Johnson, UnitedHealth Group Inc., and Abbott Laboratories. Launched in 1998 as part of Janus Investment Fund, with the related strategy originating around 2000, JFNNX is domiciled in the United States and forms part of the offerings from Janus Henderson Investors, a global asset manager formed by the 2017 merger of Janus Capital (founded 1969 in Denver, Colorado) and Henderson Global Investors (roots in 1934 in London), headquartered in London with extensive operations worldwide. Portfolio managers Andy Acker (since 2007) and Daniel Lyons (since January 2023) lead a team of health care specialists with over 95 years of combined experience. In recent developments, the fund delivered an 8.26% return in Q3 2025, outperforming the MSCI World Health Care Index by over 5 percentage points, driven by holdings like Argenx and Avidity Biosciences; Janus Henderson announced SFDR-related changes to the Global Life Sciences Fund effective November 21, 2025, alongside strategic expansions including the acquisition of a majority stake in Victory Park Capital in Q4 2024 to bolster private credit capabilities, the first close of the MENA Private Credit Fund IV at $125.5 million in October 2025 targeting $300 million, and ongoing private market initiatives supporting life sciences growth.